placebo on the time to occurrence of a composite cardiovascular outcome (nonfatal myocardial infarction, nonfatal stroke, cardiovascular death, hospitalization or urgent visit due to heart failure) and a composite renal outcome (end-stage kidney disease, 40% sustained decline in eGFR, cardiovascular death or renal death) in 10,000 individuals with atherosclerotic cardiovascular disease and/or CKD
10.1111/j.1440-1754.1982.tb01978.x Aust Paediatr J
Researchers isolated the body protection compound and studied a stable 15-amino-acid fragment of it, which became BPC-157
Hughes, J
This diversity underscores its clinical significance and highlights the complexity of the underlying mechanisms, which may involve multifactorial interactions such as inflammation, neuronal dysfunction, disruptions in the gut-brain axis, and metabolic disorders
Treatment of adults with growth hormone (GH) deficiency with recombinant human GH